IDEXX Laboratories, Inc. develops, manufactures, and distributes diagnostic products and services for the companion animal veterinary, livestock, poultry, and dairy, and water testing industries. The company operates through three primary reportable segments: the Companion Animal Group, Water Quality Products, and Livestock, Poultry, and Dairy. Its Companion Animal Group offers point-of-care diagnostic instruments, rapid assay test kits, reference laboratory services, and veterinary practice management software. Key products include the IDEXX VetLab suite of analyzers, SNAP rapid assay kits, and the VetConnect PLUS cloud-based platform. The company also provides diagnostic and health-monitoring products for livestock, poultry, and dairy, as well as water testing solutions for microbiological contaminants. IDEXX manufactures human medical point-of-care diagnostic products through its OPTI Medical Systems subsidiary. The company serves customers in developed geographies worldwide, including the U.S., Europe, Canada, Australia, Japan, New Zealand, South Africa, and South Korea. IDEXX was founded in 1983.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Instruments & Supplies Homepage idexx.com
Sector Healthcare IR page ir.idexx.com
Tags
veterinary diagnostics, point-of-care testing, reference laboratories, veterinary software, water quality testing, livestock health monitoring, rapid assay kits, diagnostic imaging, telemedicine, human medical diagnostics, IDEXX VetLab, Catalyst One Chemistry Analyzer, ProCyte One, SediVue Dx Analyzer, IDEXX inVue Dx, SNAP rapid assay test kits, SNAP 4Dx Plus, SNAP Heartworm RT, SNAP Feline Triple, IDEXX VetLab Station, VetConnect PLUS, IDEXX DecisionIQ, IDEXX Cancer Dx Panel, IDEXX Telemedicine, IDEXX Web PACS, ezyVet, VetMedStat, OPTI Medical Systems
Press page ir.idexx.com/news-events/press-releases

Metrics

Valuation  
Market cap $ 55.181B
Market cap (USD) $ 55.181B
P/E 47.19
PEG 2.95
P/BV 29.52
P/S 11.84
P/OCF 38.89
P/FCF 42.32
Dividend yield —
Turnover / mcap —
Returns  
ROE 66.2%
ROI 51.5%
ROIC 52.9%
Profit margin 24.6%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 16.0%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock Yes
Diluting (TTM) No
Debt/Equity 20.1%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 32
Quality score 44.4%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 4.304B 3.898B 3.661B 3.367B 3.215B 2.707B 2.407B 2.213B 1.969B 1.775B 1.602B 1.486B 1.377B 1.293B 1.219B 1.103B 1.032B 1.024B 922.555M 739.117M 638.095M 549.181M 475.992M 412.67M 386.081M 367.432M
Net profit 1.059B 887.867M 845.042M 679.089M 744.845M 581.776M 427.72M 377.031M 263.144M 222.045M 192.078M 181.906M 187.8M 178.267M 161.786M 141.284M 122.225M 116.169M 94.014M 93.678M 78.254M 78.332M 57.09M 45.389M 37.62M 36.632M
Free cash flow 1.057B 808.079M 772.879M 394.146M 635.997M 541.105M 304.189M 284.333M 298.892M 269.784M 133.443M 175.323M 168.384M 164.79M 168.236M 139.925M 125.534M 54.071M 69.986M 77.495M 92.353M 66.314M 100.259M 88.166M 28.983M 12.72M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 676.53 413.44 555.05 407.96 658.46 499.87 261.13 186.02 156.38 117.27 72.92 148.27 106.37 92.79 76.98 69.22 53.19 56 60.24 93.7 — — — — — —
Price performance 12m 0.64 -0.26 0.36 -0.38 0.32 0.91 0.4 0.19 0.33 0.61 -0.51 0.39 0.15 0.21 0.11 0.3 -0.05 -0.07 -0.36 — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 204M 235M 249M 269M 331M 368M 401M 457M 474M 552M
↳ YoY growth +8.6% +14.7% +6.1% +8.2% +23.1% +11.1% +8.8% +14.2% +3.5% +16.6%
↳ 5y CAGR +7.7% +11.1% +9.5% +12.1% +12.0% +12.5% +11.3% +12.9% +12.0% +10.8%
Borrowings, current (USD) — — — 0.00 50M 75M 75M 75M 168M 75M
Borrowings, non-current (USD) — — — 699M 858M 775M 694M 623M 450M 375M
Lease liabilities (USD) — — 0.00 82.8M 94.8M 107M 122M 119M 119M 128M
Cash and deposits (USD) 155M 188M 124M 90.3M 384M 144M 113M 454M 288M 180M
Intangible assets (USD) 46.2M 43.8M 41.8M 58.5M 52.5M 99M 97.7M 84.5M 112M 110M
Right-of-use assets (USD) — — 0.00 80.6M 91.2M 105M 119M 115M 116M 123M
Net debt (borrowings + leases - cash) (USD) — — — 691M 619M 813M 778M 363M 449M 398M
Cash flow detail
Operating cash flow (USD) 335M 373M 400M 459M 648M 756M 543M 907M 929M 1.18B
Purchases of property, plant and equipment (USD) -64.8M -74.4M -116M -155M -107M -120M -149M -134M -121M -125M
Purchases of intangible assets (USD) 0.00 -2.32M -7.19M -255,000 -668,000 0.00 -10M 0.00 -10M -13.6M
Change in receivables (cash effect) (USD) -22.6M -24.9M -18.4M -22.5M -60.7M -33.1M -41.4M -53.9M -28.3M -68.7M
Change in inventories (cash effect) (USD) 7.65M -19.1M -25.6M -37.3M -18.9M -52.9M -122M -28.7M -28M -789,000
Change in payables (cash effect) (USD) — — — — — — 3.47M -557,000 8.09M -8.57M
Share buybacks (cash effect) (USD) -304M -283M -369M -302M -183M -747M -820M -71.9M -837M -1.22B
Interest paid (cash effect) (USD) -31M -37.6M -34.7M -29.7M -32.4M -30.5M -39.5M -41M -33.8M -37.7M
Income taxes paid (cash effect) (USD) -74.7M -81.2M -69.7M -88M -111M -162M -240M -193M -307M -167M
Share-based compensation (USD) 19.9M 23.5M 25.2M 39.3M 31M 37.8M 49.8M 59.7M 60.3M 60M
Operating cash flow before change in receivables (USD) 357M 398M 418M 482M 709M 789M 584M 960M 957M 1.25B
Free cash flow (OCF - PPE - intangibles) (USD) 270M 297M 277M 304M 541M 636M 384M 773M 798M 1.04B
Income detail
Research and development expense (USD) 101M 109M 118M 133M 141M 161M 255M 191M 220M 251M
↳ 5y CAGR +5.9% +5.9% +6.0% +6.3% +7.2% +9.7% +18.5% +10.1% +10.5% +12.2%
Total comprehensive income (USD) 221M 270M 372M 423M 575M 745M 655M 852M 865M 1.08B
Comprehensive income to owners (USD) 221M 270M 372M 423M 574M 745M 655M 852M 865M 1.08B
Provision for credit losses (USD) 1.17M 1.88M 1.61M 662,000 4.95M — — — — —
Credit cost ratio (credit losses / average receivables) (%) 0.6% 0.9% 0.7% 0.3% 1.6% — — — — —
Reported Feb 15, 2019 Feb 16, 2018 May 1, 2019 Oct 29, 2020 Feb 16, 2023 Feb 16, 2023 Feb 21, 2025 Feb 21, 2025 Feb 21, 2025 Feb 20, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

IDEXX Laboratories Announces Third Quarter Results Bull 4 Bear 0 Results

November 02, 2026 6:30am EST

Related Documents

Third Quarter 2026 Earnings Conference Call

The following webcast contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including statements about the Company’s business prospects and estimates of the Company’s financial results for future periods. Forward-looking statements can be identified by the use of words such as "expects", "may", "can", "anticipates", "intends", "would", "will", "plans", "believes", "estimates", "projected", "should", and similar words and expressions. Our forward-looking statements include statements relating to our expectations regarding financial performance; revenue growth and EPS outlooks; operating and free cash flow forecast; projected impact of foreign currency exchange rates and interest rates; projected operating margins and expenses and capital expenditures; projected tax, tax rate and EPS benefits from share-based compensation arrangements; projected effective tax rates, reduction of average shares outstanding and net interest expense; projected net price realization; trends and other factors impacting the pet healthcare industry, including pet population demographics and U.S. clinical visits, and their anticipated effects on the Company; IDEXX inVue DxTM analyzer placements; IDEXX Cancer DxTM testing panel expansion; CoVet acquisition-related impacts; and CoVet integration plans. These statements are intended to provide management's expectations or forecasts of future events as of the date of this webcast; are based on management's estimates, projections, beliefs, and assumptions as of the date of this webcast; and are not guarantees of future performance. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, among other things, the adverse impact, and the duration, of macroeconomic events, conditions, and uncertainties, such as geopolitical instability (including wars, terrorist attacks, and armed conflicts), general economic uncertainty, changes in U.S. and other countries’ tariff and trade policies, severe weather and other natural conditions, our ability to successfully integrate CoVet, and supply chain challenges on our business, results of operations, liquidity, financial condition, and stock price, as well as the matters described under the headings "Business," "Risk Factors," "Legal Proceedings," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Quantitative and Qualitative Disclosures About Market Risk" in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and in the corresponding sections of the Company's Quarterly Report on Form 10-Q for the quarters ended March 31, 2026, June 30, 2026, and September 30, 2026, as well as those described from time to time in the Company’s other filings with the U.S. Securities and Exchange Commission available at www.sec.gov . The Company specifically disclaims any obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Cancel Continue

Earnings webcastAudio

Earnings snapshotPDF

Prepared remarksPDF

10-QHTML XBRL Zip

  • Achieves third quarter revenue growth of 10% as reported and organic and CAG Diagnostics recurring revenue growth of 11% as reported and organic.
  • Double-digit organic revenue growth was led by strong volume expansion, including benefits from IDEXX's innovations and excellent commercial execution.
  • Places over 1,900 IDEXX inVue Dx™ analyzers during the quarter, driving installed base to nearly 11,000 instruments.
  • Delivers EPS of $4.01, an increase of 18% as reported and 22% on a comparable basis, with operating margin up 100 basis points as reported and 60 basis points on a comparable basis.
  • Increases 2026 revenue guidance to $4,741 million - $4,767 million, up $32 million at midpoint, reflecting strong CAG Diagnostics recurring revenue performance.
  • Outlook for 2026 reported revenue growth raised to 10.1% - 10.8%, and CAG Diagnostics recurring revenue reported growth raised to 11.0% - 11.7%, with projected 2026 organic revenue growth of 9.3% - 10.0% and CAG Diagnostics recurring revenue organic growth of 10.3% - 11.0%.
  • Raises 2026 EPS outlook to $14.96 - $15.16, reflecting a $0.25 increase compared to prior guidance midpoint, led by a raised revenue outlook while supporting acquisition impacts.

WESTBROOK, Maine--(BUSINESS WIRE)-- IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, today announced third quarter results.

Third Quarter Results

The Company reports revenues of $1,214 million for the third quarter of 2026, an increase of 10% as reported and organic, driven by Companion Animal Group ("CAG") growth of 10% as reported and organic.

Third quarter earnings per diluted share (“EPS”) were $4.01, an increase of 18% as reported and 22% on a comparable basis. Third quarter EPS included $0.03 per share benefit from a non-operating gain on an equity investment, $0.01 per share in tax benefits from share-based compensation, and $0.04 per share benefit from year-over-year currency changes, while absorbing acquisition impacts.

“IDEXX delivered exceptional third quarter results, reflecting strong commercial execution and momentum from our innovation-driven growth strategy,” said Mike Erickson, President and Chief Executive Officer. “Innovations like IDEXX inVue Dx with FNA, and IDEXX Cancer Dx becoming a multi-cancer panel, are helping practices detect disease earlier and work more efficiently. In software, we advanced our capabilities with the acquisition of CoVet, an AI clinical assistant that supports veterinary team productivity and diagnostics utilization, creating more value for our customers and shareholders."

Third Quarter Performance Highlights

Companion Animal Group (“CAG”)

CAG revenue growth was led by CAG Diagnostics recurring revenue growth of 11% as reported and organic, including 13% reported and 14% organic gains in International regions and 10% reported and organic growth in the U.S., outpacing sector growth levels.

Additional U.S. companion animal practice key metrics are available in the Q3 2026 Earnings Snapshot accessible on the IDEXX website, www.idexx.com/investors .

Strong same-store volume growth, IDEXX innovation benefits, net customer gains and premium instrument installed base expansion drove double-digit CAG Diagnostics recurring revenue growth.

  • IDEXX VetLab™ consumables revenues grew 14% reported and 15% organic, supported by net new customer growth, including 11% expansion of the IDEXX global premium instrument installed base, utilization expansion with benefits from recent product launches and net price gains.
  • Reference laboratory diagnostic and consulting services generated 10% reported and organic revenue growth, driven by testing volume growth, net new customer gains, and price realization.
  • Rapid assay products revenues increased 1% as reported and on an organic basis, driven by net price benefits, offsetting lower testing volumes.

CAG Diagnostics capital instrument revenues were flat on an as reported and an organic basis, with benefits from over 1,900 IDEXX inVue Dx placements during the quarter.

Veterinary software, services and diagnostic imaging systems revenues grew 11% on a reported and 10% on an organic basis for the quarter, with benefits from a strong quarter of diagnostic imaging systems installations, led by ImageVue™ DR50 Plus.

Water

Water revenues grew 8% as reported and organic for the quarter, driven by growth in North America.

Livestock, Poultry and Dairy (“LPD”)

LPD revenues increased 3% as reported and organic for the quarter, led by growth in the Americas.

Gross Profit and Operating Profit

Gross profit increased 12% as reported and 12% on a comparable basis. Gross margin of 62.9% increased 110 basis points as reported and 90 basis points on a comparable basis, supported by strong recurring revenue volume gains, operational productivity initiatives, and net price realization.

Operating margin was 33.1% for the quarter, higher than the prior year period by 100 basis points as reported and by 60 basis points on a comparable basis. Operating margin results reflect a 10% operating expense increase as reported and 11% growth on a comparable basis. Operating expense growth supported expansion of IDEXX's commercial capabilities and advancement of the Company's innovation agenda, while absorbing acquisition impacts, including transaction-related costs.

2026 Growth and Financial Performance Outlook

The Company is updating its full year revenue growth guidance range to $4,741 million - $4,767 million, or reported growth of 10.1% - 10.8%, an increase of $32 million at midpoint, including $5 million related to the recent CoVet acquisition. The Company is increasing its outlook for organic revenue growth to 9.3% - 10.0%, an increase of 0.6% at midpoint, reflecting operational performance.

The Company lowered its full year reported operating margin outlook to 32.1% - 32.3%, bringing the projected full year operating profit margin expansion to 50 - 70 basis points as reported and on a comparable basis. The updated guidance includes acquisition-related impacts.

The Company updated its EPS outlook range to $14.96 - $15.16, a $0.25 increase compared to prior guidance midpoint, reflecting 15% reported and 16% comparable growth.

The following table provides the Company's updated outlook for annual key financial metrics in 2026 with a comparison to the prior outlook:

Scroll to view ↔

Amounts in millions except per share data and percentages
2026 Growth and Financial Performance Outlook
Updated Prior
Revenue $4,741 - $4,767 $4,700 - $4,745
Reported growth 10.1% - 10.8% 9.1% - 10.3%
Organic growth 9.3% - 10.0% 8.5% - 9.7%
CAG Diagnostics Recurring Revenue Growth
Reported growth 11.0% - 11.7% 10.1% - 11.3%
Organic growth 10.3% - 11.0% 9.5% - 10.7%
Operating Margin 32.1% - 32.3% 32.3% - 32.5%
Operating margin expansion 50 bps - 70 bps 70 bps - 90 bps
Comparable margin expansion 50 bps - 70 bps 70 bps - 90 bps
EPS $14.96 - $15.16 $14.69 - $14.94
Reported growth 14% - 16% 12% - 14%
Comparable growth 15% - 16% 13% - 15%
Other Key Metrics
Net interest expense ~ $32 ~ $35
Share-based compensation tax benefit ~ $19 ~ $19
Share-based compensation tax rate benefit ~ 1.3% ~ 1.3%
Effective tax rate ~ 20.5% ~ 21.1%
Share-based compensation EPS impact ~ $0.24 ~ $0.24
Reduction in average shares outstanding ~ 2% 1.5% - 2%
Operating Cash Flow (% of Net Income) 110% - 120% 110% - 120%
Free Cash Flow (% of Net Income) 95% - 100% 90% - 100%
Capital Expenditures ~ $160 ~ $180

The following table outlines estimates of foreign currency exchange rate impacts, net of foreign currency hedging transactions, and foreign currency exchange rate assumptions reflected in the above financial performance outlook for 2026.

Scroll to view ↔

Estimated Foreign Currency Exchange Rate Impacts 2026
Revenue growth rate impact ~0.7%
CAG Diagnostics recurring revenue growth rate impact ~0.7%
Operating margin growth impact ~ 30 bps
EPS impact ~ $0.25
EPS growth impact ~ 2%
Go-Forward Foreign Currency Exchange Rate Assumptions 2026
In U.S. dollars
euro $1.12
British pound $1.32
Canadian dollar $0.70
Australian dollar $0.69
Relative to the U.S. dollar
Japanese yen ¥160
Chinese renminbi ¥6.80
Brazilian real R$5.05

Conference Call and Webcast Information

IDEXX Laboratories, Inc. will host a conference call today at 8:30 a.m. (ET) to discuss its third quarter 2026 results and management’s outlook. Individuals can access a live webcast of the conference call through a link on the IDEXX website, www.idexx.com/investors . An archived edition of the webcast will be available after 1:00 p.m. (ET) via the same link and will remain available for one year. The live call also will be accessible by telephone. To listen to the live conference call, please dial 1-800-330-6730 or 1-213-279-1575 and reference passcode 715328.

2027 VMX Event

IDEXX Laboratories, Inc. will host an Investor and Analyst Session at VMX in Orlando, Florida on Monday, January 18th at 1:00 p.m. (ET), highlighting IDEXX's next point-of-care analyzer, IDEXX MultiCue Dx™. On-site participation is limited and advance registration for the in-person event is required; institutional investors and analysts interested in attending should contact [email protected] . A live webcast and accompanying slide presentations will be available at www.idexx.com/investors . An archived webcast replay of the event will be available approximately one hour following the event via the same link.

About IDEXX Laboratories, Inc.

IDEXX is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions—to advance medical care, improve efficiency, and build thriving practices. Our innovations also help measure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500© Index. Headquartered in Maine, IDEXX employs approximately 11,000 people and offers solutions and products to customers in more than 175 countries and territories. For more information about IDEXX, visit www.idexx.com .

Note Regarding Forward-Looking Statements

This earnings release and the statements to be made in the accompanying earnings conference call contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including statements about the Company’s business prospects and estimates of the Company’s financial results for future periods. Forward-looking statements are included above under "2026 Growth and Financial Performance Outlook" and elsewhere and can be identified by the use of words such as "expects", "may", "can", "anticipates", "intends", "would", "will", "plans", "believes", "estimates", "projected", "should", and similar words and expressions. Our forward-looking statements include statements relating to our expectations regarding financial performance; revenue growth and EPS outlooks; operating and free cash flow forecast; projected impact of foreign currency exchange rates and interest rates; projected operating margins and expenses and capital expenditures; projected tax, tax rate and EPS benefits from share-based compensation arrangements; projected effective tax rates, reduction of average shares outstanding and net interest expense; projected net price realization; trends and other factors impacting the pet healthcare industry, including pet population demographics and U.S. clinical visits, and their anticipated effects on the Company; IDEXX inVue Dx analyzer placements; IDEXX Cancer Dx_™_ testing panel expansion; CoVet acquisition-related impacts; and CoVet integration plans. These statements are intended to provide management's expectations or forecasts of future events as of the date of this earnings release; are based on management's estimates, projections, beliefs, and assumptions as of the date of this earnings release; and are not guarantees of future performance. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, among other things, the adverse impact, and the duration, of macroeconomic events, conditions, and uncertainties, such as geopolitical instability (including wars, terrorist attacks, and armed conflicts), general economic uncertainty, changes in U.S. and other countries’ tariff and trade policies, severe weather and other natural conditions, our ability to successfully integrate CoVet, and supply chain challenges on our business, results of operations, liquidity, financial condition, and stock price, as well as the matters described under the headings "Business," "Risk Factors," "Legal Proceedings," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Quantitative and Qualitative Disclosures About Market Risk" in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and in the corresponding sections of the Company's Quarterly Report on Form 10-Q for the quarters ended March 31, 2026, June 30, 2026, and September 30, 2026, as well as those described from time to time in the Company’s other filings with the U.S. Securities and Exchange Commission available at www.sec.gov . The Company specifically disclaims any obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Statement Regarding Non-GAAP Financial Measures

The following defines terms and conventions and provides reconciliations regarding certain measures used in this earnings release and/or the accompanying earnings conference call that are not required by, or presented in accordance with, generally accepted accounting principles in the United States of America ("GAAP"), otherwise referred to as non-GAAP financial measures. To supplement the Company’s consolidated results presented in accordance with GAAP, the Company has disclosed non-GAAP financial measures that exclude or adjust certain items. Management believes these non-GAAP financial measures provide useful supplemental information for its and investors’ evaluation of the Company’s business performance and liquidity and are useful for period-over-period comparisons of the performance of the Company’s business and its liquidity and to the performance and liquidity of our peers. While management believes that these non-GAAP financial measures are useful in evaluating the Company’s business, this information should be considered as supplemental in nature and should not be considered in isolation or as a substitute for the related financial information prepared in accordance with GAAP. In addition, these non-GAAP financial measures may not be the same as similarly titled measures reported by other companies.

Constant currency - Constant currency references are non-GAAP financial measures which exclude the impact of changes in foreign currency exchange rates and are consistent with how management evaluates our performance and comparisons with prior and future periods. We estimate the net impacts of currency on our revenue, gross profit, operating profit, and EPS results by restating results to the average exchange rates or exchange rate assumptions for the comparative period, which includes adjusting for the estimated impacts of foreign currency hedging transactions and certain impacts on our effective tax rates. These estimated currency changes impacted third quarter 2026 results as follows: increased gross profit growth by 0.2%, increased gross margin expansion 20 basis points, decreased operating expense growth by 0.9%, increased operating profit growth by 1.2%, increased operating profit margin growth by 40 basis points, and increased EPS growth by 1.2%. Constant currency revenue growth represents the percentage change in revenue during the applicable period, as compared to the prior year period, excluding the impact of changes in foreign currency exchange rates. See the supplementary analysis of results below for revenue percentage change from currency for the three and nine months ended September 30, 2026 and refer to the 2026 Growth and Financial Performance Outlook section of this earnings release for estimated foreign currency exchange rate impacts on 2026 projections and estimates.

Growth and organic revenue growth - All references to growth and organic growth refer to growth compared to the equivalent prior year period unless specifically noted. Organic revenue growth is a non-GAAP financial measure that represents the percentage change in revenue, as compared to the same period for the prior year, net of the effect of changes in foreign currency exchange rates, certain business acquisitions, and divestitures. Management believes that reporting organic revenue growth provides useful information to investors by facilitating easier comparisons of our revenue performance with prior and future periods and to the performance of our peers. Organic revenue growth should be considered in addition to, and not as a replacement of or a superior measure to, revenue growth reported in accordance with GAAP. See the supplementary analysis of results below for a reconciliation of reported revenue growth to organic revenue growth for the three and nine months ended September 30, 2026. Please refer to the constant currency note above for a summary of foreign currency exchange rate impacts. Please refer to the 2026 Growth and Financial Performance Outlook section of this earnings release for estimated full year 2026 organic revenue growth for the Company and CAG Diagnostics recurring revenue growth. The percentage change in revenue resulting from acquisitions represents revenues during the current year period, limited to the initial 12 months from the date of the acquisition, that are directly attributable to business acquisitions. Revenue from acquisitions is expected to have an immaterial impact on projected full year 2026 revenue growth and no impact on CAG Diagnostics recurring revenue growth.

We exclude from organic revenue growth the effect of changes in foreign currency exchange rates because changes in foreign currency exchange rates are not under management’s control, are subject to volatility, and can obscure underlying business trends. We calculate the impact on revenue resulting from changes in foreign currency exchange rates by applying the difference between the weighted average exchange rates during the current period and the comparable prior year period to foreign currency denominated revenues for the prior year period.

We also exclude from organic revenue growth the effect of certain business acquisitions and divestitures because the nature, size, and number of these transactions can vary dramatically from period to period, and because they either require or generate cash as an inherent consequence of the transaction, and therefore can also obscure underlying business and operating trends. We consider acquisitions to be a business when all three elements of inputs, processes, and outputs are present, consistent with ASU 2017-01, “Business Combinations: (Topic 805) Clarifying the Definition of a Business.” We do not consider acquired assets to be a business if substantially all the fair value of the assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. A typical acquisition that we do not consider a business is a customer relationship asset acquisition, which does not have all elements necessary to operate a business, such as employees or infrastructure. Revenue from these customers acquired is included in organic revenue growth because we believe the efforts required to convert and retain these acquired customers are similar in nature to our efforts to obtain and retain our existing customer base.

Comparable growth metrics - Comparable gross profit growth, comparable gross margin gain (or growth), comparable operating expense growth, comparable operating profit growth and comparable operating margin gain (or growth) are non-GAAP financial measures and exclude the impact of changes in foreign currency exchange rates and non-recurring or unusual items (if any). Please refer to the constant currency note above for a summary of foreign currency exchange rate impacts. Management believes that reporting comparable gross profit growth, comparable gross margin gain (or growth), comparable operating expense growth, comparable operating profit growth and comparable operating margin gain (or growth) provides useful information to investors because it enables better period-over-period comparisons of the fundamental financial results by excluding items that vary independent of performance and provides greater transparency to investors regarding key metrics used by management. Comparable gross profit growth, comparable gross margin gain (or growth), comparable operating expense growth, comparable operating profit growth and comparable operating margin gain (or growth) should be considered in addition to, and not as replacements of or superior measures to, gross profit growth, gross margin gain, operating expense growth, operating profit growth and operating margin gain reported in accordance with GAAP.

The reconciliation of these non-GAAP financial measures is as follows:

Scroll to view ↔

Three Months Ended Year-over-Year Nine Months Ended Year-over-Year
September 30, September 30, Change September 30, September 30, Change
Dollar amounts in thousands 2026 2025 2026 2025
Gross profit and growth (as reported) $764,298 $683,354 12% $2,266,124 $2,001,465 13%
Gross margin and margin gain 62.9% 61.8% 110 bps 63.4% 62.3% 120 bps
Less: comparability adjustments
Change from currency 1,091 — 29,073 —
Comparable gross profit and growth $763,207 $683,354 12% $2,237,051 $2,001,465 12%
Comparable gross margin and margin gain 62.7% 61.8% 90 bps 63.3% 62.3% 100 bps
Operating expenses and growth (as reported) $361,950 $328,508 10% $1,075,624 $957,039 12%
Less: comparability adjustments
Change from currency (3,043) — 4,685 —
Loss on equity investment — — 5,000 —
Now-concluded litigation matter — — — (8,600)
Comparable operating expense and growth $364,993 $328,508 11% $1,065,939 $965,639 10%
Operating profit and growth (as reported) $402,348 $354,846 13% $1,190,500 $1,044,426 14%
Operating margin and margin gain 33.1% 32.1% 100 bps 33.3% 32.5% 80 bps
Less: comparability adjustments
Change from currency 4,134 — 24,388 —
Loss on equity investment — — (5,000) —
Now-concluded litigation matter — — — 8,600
Comparable operating profit and growth $398,214 $354,846 12% $1,171,112 $1,035,826 13%
Comparable operating margin and margin gain 32.7% 32.1% 60 bps 33.1% 32.2% 90 bps
Amounts presented may not recalculate due to rounding.

Projected 2026 comparable operating margin expansion outlined in the 2026 Growth and Financial Performance Outlook section of this earnings release reflects the following adjustments: (i) full year 2026 reported operating margin adjusted for a $5 million unfavorable impact of loss on an equity investment; (ii) adjustment to projected 2026 operating margin for a positive impact from year-over-year foreign currency exchange rate changes at noted exchange rates; and (iii) adjustment to 2025 operating margin for the positive impact of the approximately $9 million discrete litigation expense accrual adjustment in the first quarter of 2025.

These impacts described above reconcile reported gross profit growth, gross margin gain, operating expense growth, operating profit growth and operating margin gain (including projected 2026) to comparable gross profit growth, comparable gross margin gain, comparable operating expense growth, comparable operating profit growth and comparable operating margin gain for the Company.

Comparable EPS growth - Comparable EPS growth is a non-GAAP financial measure that represents the percentage change in earnings per share (diluted) ("EPS") for a measurement period, as compared to the prior base period, net of the impact of changes in foreign currency exchange rates from the prior base period and excluding the tax benefits of share-based compensation activity under ASU 2016-09, "Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting," and non-recurring or unusual items (if any). Management believes comparable EPS growth is a more useful way to measure the Company’s business performance than EPS growth because it enables better period-over-period comparisons of the fundamental financial results by excluding items that vary independent of performance and provides greater transparency to investors regarding a key metric used by management. Comparable EPS growth should be considered in addition to, and not as a replacement of or a superior measure to, EPS growth reported in accordance with GAAP. Please refer to the constant currency note above for a summary of foreign currency exchange rate impacts.

The reconciliation of this non-GAAP financial measure is as follows:

Scroll to view ↔

Three Months Ended Year-over-Year Nine Months Ended Year-over-Year
September 30, September 30, Growth September 30, September 30, Growth
2026 2025 2026 2025
Earnings per share (diluted) and growth $4.01 $3.40 18% $11.75 $9.99 18%
Less: comparability adjustments
Share-based compensation activity 0.01 0.17 0.24 0.28
Loss on equity investment — — (0.05) —
Now-concluded litigation matter — — — 0.08
Change from currency 0.04 — 0.24 —
Comparable EPS and growth $3.96 $3.24 22% $11.32 $9.63 18%
Amounts presented may not recalculate due to rounding.

Projected 2026 comparable EPS growth outlined in the 2026 Growth and Financial Performance Outlook section of this earnings release reflects the following adjustments: (i) adjustment to projected full year 2026 reported EPS for estimated positive year-over-year foreign currency exchange rate change impact of $0.25 at noted exchange rates; (ii) adjustment to projected full year 2026 reported EPS for estimated positive impact of share-based compensation activity of $0.24; (iii) adjustment to projected full year 2026 EPS of $0.05 for unfavorable impact of a loss on an equity investment; (iv) adjustment to full year 2025 reported EPS for a positive $0.08 impact from the discrete litigation expense accrual adjustment in the first quarter of 2025; and (v) adjustment to full year 2025 reported EPS for positive impact of share-based compensation activity of $0.35.

These impacts and those described in the constant currency note above reconcile reported EPS growth (including projected 2026 reported EPS growth) to comparable EPS growth for the Company.

Segment and Other Income from Operations - We report segment income from operations in our Segment Information table below. Segment income from operations is a non-GAAP financial measure that adjusts for the impact of foreign currency transaction gains and losses and should be considered in addition to, and not as a replacement for, or superior measure to, income from operations. We exclude foreign currency transaction gains and losses for each reportable segment (CAG, Water, and LPD) from segment income from operations and report the full amount of foreign currency transaction gains and losses in Other. We believe that reporting segment income from operations provides supplemental analysis to help investors further evaluate each reportable segment’s business performance by excluding foreign currency transaction gains and losses, which are centrally managed by our corporate treasury function and which we do not consider relevant for assessing the results of each reportable segment’s operations.

The reconciliation of this non-GAAP financial measure is as follows for the three and nine months ended September 30, 2026 and 2025:

Scroll to view ↔

Amounts in thousands Three Months Ended September 30,
2026 2025
Income from Operations Impact from Foreign Currency Segment and Other Income from Operations Income from Operations Impact from Foreign Currency Segment and Other Income from Operations
CAG $370,216 ($713) $369,503 $327,095 $1,376 $328,471
Water 29,624 (50) 29,574 26,311 104 26,415
LPD 1,948 (49) 1,899 364 107 471
Other 560 812 1,372 1,076 (1,587) (511)
Total $402,348 $— $402,348 $354,846 $— $354,846

Scroll to view ↔

Amounts in thousands Nine Months Ended September 30,
2026 2025
Income from Operations Impact from Foreign Currency Segment and Other Income from Operations Income from Operations Impact from Foreign Currency Segment and Other Income from Operations
CAG $1,100,450 ($109) $1,100,341 $969,649 $2,454 $972,103
Water 83,525 (8) 83,517 71,691 183 71,874
LPD 5,605 (5) 5,600 (98) 189 91
Other 920 122 1,042 3,184 (2,826) 358
Total $1,190,500 $— $1,190,500 $1,044,426 $— $1,044,426

Free cash flow - Free cash flow is a non-GAAP financial measure and means, with respect to a measurement period, the cash generated from operations during that period, reduced by the Company’s investments in property and equipment. Management believes free cash flow is a useful measure because it indicates the cash the operations of the business are generating after appropriate reinvestment for recurring investments in property and equipment that are required to operate the business. Free cash flow should be considered in addition to, and not as a replacement of or a superior measure to, net cash provided by operating activities. See the supplementary analysis of results below for our calculation of free cash flow for the three and nine months ended September 30, 2026 and 2025. To estimate projected 2026 free cash flow, we have deducted projected purchases of property and equipment (also referred to as capital expenditures) of approximately $160 million. Free cash flow conversion, or the net income to free cash flow ratio, is a non-GAAP financial measure that is defined as free cash flow, with respect to a measurement period, divided by net income for the same period. To calculate trailing twelve-month net income to free cash flow ratio for the twelve months ended September 30, 2026, we have deducted purchases of property and equipment of approximately $115 million from net cash provided from operating activities of approximately $1,419 million, divided by net income of approximately $1,182 million.

Notes and Definitions

Discrete litigation expense accrual - During the first quarter of 2025, the Company reduced its previously established $89.0 million accrual related to a concluded litigation matter by approximately $9 million, which represented our best estimate at that time of the amount of the loss.

Concluded litigation matter - The Company was a defendant in a litigation matter involving an alleged breach of contract for underpayment of royalty payments made from 2004 through 2017 under an expired patent license agreement, and the trial court ruled in favor of the plaintiff in 2020. Following appeals and in light of the appellate court's April 3, 2025 decision, on April 17, 2025, the Company paid the judgment of approximately $80 million, and the plaintiff executed a satisfaction and release of judgment, which was filed with the trial court on the same date, concluding this matter.

Scroll to view ↔

IDEXX Laboratories, Inc. and Subsidiaries
Condensed Consolidated Statement of Operations
Amounts in thousands except per share data (Unaudited)
Three Months Ended Nine Months Ended
September 30, September 30, September 30, September 30,
2026 2025 2026 2025
Revenue: Revenue $1,214,237 $1,105,239 $3,571,642 $3,213,123
Expenses and Income: Cost of revenue 449,939 421,885 1,305,518 1,211,658
Gross profit 764,298 683,354 2,266,124 2,001,465
Sales and marketing 169,850 159,157 516,377 476,487
General and administrative 123,283 105,936 359,213 296,178
Research and development 68,817 63,415 200,034 184,374
Total operating expense 361,950 328,508 1,075,624 957,039
Income from operations 402,348 354,846 1,190,500 1,044,426
Non-operating income (expense), net (3,023) (10,075) (18,509) (27,219)
Income before provision for income taxes 399,325 344,771 1,171,991 1,017,207
Provision for income taxes 82,180 70,161 237,988 205,931
Net Income: Net income attributable to stockholders $317,145 $274,610 $934,003 $811,276
Earnings per share: Basic $4.02 $3.43 $11.80 $10.06
Earnings per share: Diluted $4.01 $3.40 $11.75 $9.99
Shares outstanding: Basic 78,825 80,096 79,139 80,605
Shares outstanding: Diluted 79,049 80,675 79,512 81,207

Scroll to view ↔

IDEXX Laboratories, Inc. and Subsidiaries
Selected Operating Information (Unaudited)
Three Months Ended Nine Months Ended
September 30, September 30, September 30, September 30,
2026 2025 2026 2025
Operating Ratios Gross profit 62.9% 61.8% 63.4% 62.3%
(as a percentage of revenue): Sales, marketing, general and administrative expense 24.1% 24.0% 24.5% 24.0%
Research and development expense 5.7% 5.7% 5.6% 5.7%
Income from operations1 33.1% 32.1% 33.3% 32.5%
1Amounts presented may not recalculate due to rounding.

Scroll to view ↔

IDEXX Laboratories, Inc. and Subsidiaries
Segment and Other Information
Amounts in thousands (Unaudited)
Three Months Ended
September 30, 2026 Percent of Revenue September 30, 2025 Percent of Revenue
Revenue: CAG $1,115,968 $1,012,534
Water 58,836 54,297
LPD 34,828 33,944
Other 4,605 4,464
Total $1,214,237 $1,105,239
Gross Profit: CAG $701,345 62.8% $627,456 62.0%
Water 42,714 72.6% 38,057 70.1%
LPD 18,310 52.6% 15,945 47.0%
Other 1,929 41.9% 1,896 42.5%
Total $764,298 62.9% $683,354 61.8%
Income from Operations: CAG $369,503 33.1% $328,471 32.4%
Water 29,574 50.3% 26,415 48.6%
LPD 1,899 5.5% 471 1.4%
Other 1,372 29.8% (511) (11.4%)
Total $402,348 33.1% $354,846 32.1%

Scroll to view ↔

Nine Months Ended
September 30, 2026 Percent of Revenue September 30, 2025 Percent of Revenue
Revenue: CAG $3,288,256 $2,954,813
Water 167,665 150,619
LPD 102,492 94,302
Other 13,229 13,389
Total $3,571,642 $3,213,123
Gross Profit: CAG $2,084,641 63.4% $1,844,381 62.4%
Water 122,849 73.3% 105,641 70.1%
LPD 53,871 52.6% 45,239 48.0%
Other 4,763 36.0% 6,204 46.3%
Total $2,266,124 63.4% $2,001,465 62.3%
Income from Operations: CAG $1,100,341 33.5% $972,103 32.9%
Water 83,517 49.8% 71,874 47.7%
LPD 5,600 5.5% 91 0.1%
Other 1,042 7.9% 358 2.7%
Total $1,190,500 33.3% $1,044,426 32.5%

Scroll to view ↔

IDEXX Laboratories, Inc. and Subsidiaries
Revenues and Revenue Growth Analysis by Product and Service Categories and by Domestic and International Markets
Amounts in thousands (Unaudited)
Three Months Ended
September 30, 2026 September 30, 2025 Dollar Change Reported Revenue Growth1 Percentage Change from Currency Percentage Change from Acquisitions Organic Revenue Growth1
Net Revenue
CAG $1,115,968 $1,012,534 $103,434 10.2% (0.2%) 0.1 % 10.4%
United States 725,876 668,418 57,458 8.6% — 0.1 % 8.5%
International 390,092 344,116 45,976 13.4% (0.7%) — 14.0%
Water $58,836 $54,297 $4,539 8.4% 0.6% — 7.8%
United States 31,297 28,070 3,227 11.5% — — 11.5%
International 27,539 26,227 1,312 5.0% 1.1% — 3.9%
LPD $34,828 $33,944 $884 2.6% (0.4%) — 3.0%
United States 7,651 6,861 790 11.5% — — 11.5%
International 27,177 27,083 94 0.3% (0.5%) — 0.8%
Other $4,605 $4,464 $141 3.2% — — 3.2%
Total Company $1,214,237 $1,105,239 $108,998 9.9% (0.2%) 0.1 % 10.0%
United States 766,582 705,040 61,542 8.7% — 0.1 % 8.6%
International 447,655 400,199 47,456 11.9% (0.5%) — 12.4%

Scroll to view ↔

Three Months Ended
September 30, 2026 September 30, 2025 Dollar Change Reported Revenue Growth1 Percentage Change fromCurrency Percentage Change from Acquisitions Organic Revenue Growth1
Net CAG Revenue
CAG Diagnostics recurring revenue: $967,351 $873,273 $94,078 10.8% (0.2%) — 11.0%
IDEXX VetLab consumables 443,245 387,813 55,432 14.3% (0.3%) — 14.6%
Rapid assay products 89,135 88,638 497 0.6% (0.2%) — 0.7%
Reference laboratory diagnostic and consulting services 399,079 362,725 36,354 10.0% (0.2%) — 10.2%
CAG Diagnostics services and accessories 35,892 34,097 1,795 5.3% (0.1%) — 5.4%
CAG Diagnostics capital – instruments $51,492 $51,479 $13 — (0.3%) — 0.4%
Veterinary software, services and diagnostic imaging systems: $97,125 $87,782 $9,343 10.6% 0.1% 0.7% 9.9%
Recurring revenue 77,472 70,988 6,484 9.1% 0.2% 0.8% 8.2%
Systems and hardware 19,653 16,794 2,859 17.0% — — 17.0%
Net CAG revenue $1,115,968 $1,012,534 $103,434 10.2% (0.2%) 0.1% 10.4%

Scroll to view ↔

Three Months Ended
September 30, 2026 September 30, 2025 Dollar Change Reported Revenue Growth1 Percentage Change from Currency Percentage Change from Acquisitions Organic Revenue Growth1
CAG Diagnostics recurring revenue: $967,351 $873,273 $94,078 10.8% (0.2%) — 11.0%
United States 620,322 565,951 54,371 9.6% — — 9.6%
International 347,029 307,322 39,707 12.9% (0.7%) — 13.6%
1See Statements Regarding Non-GAAP Financial Measures, above. Amounts presented may not recalculate due to rounding.

Scroll to view ↔

IDEXX Laboratories, Inc. and Subsidiaries
Revenues and Revenue Growth Analysis by Product and Service Categories and by Domestic and International Markets
Amounts in thousands (Unaudited)
Nine Months Ended
September 30, 2026 September 30, 2025 Dollar Change Reported Revenue Growth1 Percentage Change from Currency Percentage Change from Acquisitions Organic Revenue Growth1
Net Revenue
CAG $3,288,256 $2,954,813 $333,443 11.3% 1.1% — 10.2%
United States 2,151,668 1,976,804 174,864 8.8% — — 8.8%
International 1,136,588 978,009 158,579 16.2% 3.3% — 13.0%
Water $167,665 $150,619 $17,046 11.3% 2.0% — 9.3%
United States 87,311 77,663 9,648 12.4% — — 12.4%
International 80,354 72,956 7,398 10.1% 4.0% — 6.2%
LPD $102,492 $94,302 $8,190 8.7% 2.3% — 6.3%
United States 20,643 18,416 2,227 12.1% — — 12.1%
International 81,849 75,886 5,963 7.9% 2.9% — 5.0%
Other $13,229 $13,389 ($160) (1.2%) — — (1.2%)
Total Company $3,571,642 $3,213,123 $358,519 11.2% 1.1% — 10.0%
United States 2,264,782 2,077,770 187,012 9.0% — — 9.0%
International 1,306,860 1,135,353 171,507 15.1% 3.3% — 11.9%

Scroll to view ↔

Nine Months Ended
September 30, 2026 September 30, 2025 Dollar Change Reported Revenue Growth1 Percentage Change fromCurrency Percentage Change from Acquisitions Organic Revenue Growth1
Net CAG Revenue
CAG Diagnostics recurring revenue: $2,862,377 $2,557,535 $304,842 11.9% 1.1% — 10.8%
IDEXX VetLab consumables 1,286,164 1,107,704 178,460 16.1% 1.6% — 14.5%
Rapid assay products 275,648 272,912 2,736 1.0% 0.4% — 0.6%
Reference laboratory diagnostic and consulting services 1,191,987 1,074,825 117,162 10.9% 0.8% — 10.1%
CAG Diagnostics services and accessories 108,578 102,094 6,484 6.4% 1.5% — 4.9%
CAG Diagnostics capital – instruments $141,115 $142,073 ($958) (0.7%) 0.8% — (1.4%)
Veterinary software, services and diagnostic imaging systems: $284,764 $255,205 $29,559 11.6% 0.5% 0.2% 10.9%
Recurring revenue 227,351 205,735 21,616 10.5% 0.6% 0.3% 9.7%
Systems and hardware 57,413 49,470 7,943 16.1% 0.2% — 15.8%
Net CAG revenue $3,288,256 $2,954,813 $333,443 11.3% 1.1% — 10.2%

Scroll to view ↔

Nine Months Ended
September 30, 2026 September 30, 2025 Dollar Change Reported Revenue Growth1 Percentage Change from Currency Percentage Change from Acquisitions Organic Revenue Growth1
CAG Diagnostics recurring revenue: $2,862,377 $2,557,535 $304,842 11.9% 1.1% — 10.8%
United States 1,845,309 1,677,937 167,372 10.0% — — 10.0%
International 1,017,068 879,598 137,470 15.6% 3.3% — 12.3%
1See Statements Regarding Non-GAAP Financial Measures, above. Amounts presented may not recalculate due to rounding.

Scroll to view ↔

IDEXX Laboratories, Inc. and Subsidiaries
Condensed Consolidated Balance Sheet
Amounts in thousands (Unaudited)
September 30, 2026 December 31, 2025
Assets: Current Assets:
Cash and cash equivalents $197,536 $180,070
Accounts receivable, net 615,799 552,378
Inventories 390,874 377,756
Other current assets 295,795 303,623
Total current assets 1,500,004 1,413,827
Property and equipment, net 732,131 747,380
Other long-term assets, net 1,474,974 1,189,552
Total assets $3,707,109 $3,350,759
Liabilities and Stockholders'
Equity: Current Liabilities:
Accounts payable $154,086 $110,408
Accrued liabilities 520,957 530,147
Line of credit 474,000 398,000
Current portion of long-term debt 74,998 74,995
Deferred revenue 40,181 35,264
Total current liabilities 1,264,222 1,148,814
Long-term debt, net of current portion 299,879 374,842
Other long-term liabilities, net 273,831 221,720
Total long-term liabilities 573,710 596,562
Total stockholders' equity 1,869,177 1,605,383
Total liabilities and stockholders' equity $3,707,109 $3,350,759

Scroll to view ↔

IDEXX Laboratories, Inc. and Subsidiaries
Selected Balance Sheet Information (Unaudited)
September 30, 2026 June 30, 2026 March 31, 2026 December 31, 2025 September 30, 2025
Selected Balance Sheet Information: Days sales outstanding1 46.7 46.2 46.2 46.8 46.5
Inventory turns2 1.5 1.4 1.4 1.6 1.5
1Days sales outstanding represents the average of the accounts receivable balances at the beginning and end of each quarter divided by revenue for that quarter, the result of which is then multiplied by 91.25 days.
2Inventory turns are calculated as the ratio of our inventory-related cost of revenue for the quarter multiplied by four, divided by the average inventory balances at the beginning and end of each quarter.

Scroll to view ↔

IDEXX Laboratories, Inc. and Subsidiaries
Condensed Consolidated Statement of Cash Flows
Amounts in thousands (Unaudited)
Nine Months Ended
September 30, 2026 September 30, 2025
Operating: Cash Flows from Operating Activities:
Net income $934,003 $811,276
Non-cash adjustments to net income 198,224 259,262
Changes in assets and liabilities (69,100) (244,493)
Net cash provided by operating activities 1,063,127 826,045
Investing: Cash Flows from Investing Activities:
Purchases of property and equipment (85,560) (95,242)
Purchases of equity investments (1,695) (756)
Proceeds from equity investments 4,111 —
Acquisitions (227,122) (13,350)
Proceeds from net investment hedges 3,126 1,239
Net cash used by investing activities (307,140) (108,109)
Financing: Cash Flows from Financing Activities:
Borrowings under credit facility, net 76,000 205,000
Payments of senior notes (75,000) (103,386)
Repurchases of common stock (810,014) (979,190)
Proceeds from exercises of stock options and employee stock purchase plans 82,551 75,493
Shares withheld for statutory tax withholding payments on restricted stock (11,003) (7,179)
Net cash used by financing activities (737,466) (809,262)
Net effect of changes in exchange rates on cash (1,055) 11,226
Net increase (decrease) in cash and cash equivalents 17,466 (80,100)
Cash and cash equivalents, beginning of period 180,070 288,266
Cash and cash equivalents, end of period $197,536 $208,166

Scroll to view ↔

IDEXX Laboratories, Inc. and Subsidiaries
Free Cash Flow
Amounts in thousands (Unaudited)
Three Months Ended Nine Months Ended
September 30, 2026 September 30, 2025 September 30, 2026 September 30, 2025
Free Cash Flow: Net cash provided by operating activities $449,717 $402,340 $1,063,127 $826,045
Investing cash flows attributable to purchases of property and equipment (28,930) (31,114) (85,560) (95,242)
Free cash flow1 $420,787 $371,226 $977,567 $730,803
1See Statement Regarding Non-GAAP Financial Measures, above.

Scroll to view ↔

IDEXX Laboratories, Inc. and Subsidiaries
Common Stock Repurchases
Amounts in thousands except per share data (Unaudited)
Three Months Ended Nine Months Ended
September 30, 2026 September 30, 2025 September 30, 2026 September 30, 2025
Shares repurchased in the open market 199 411 1,369 2,055
Shares acquired through employee surrender for statutory tax withholding — — 17 16
Total shares repurchased 199 411 1,386 2,071
Cost of shares repurchased in the open market $111,819 $241,568 $804,698 $978,313
Cost of shares for employee surrenders 150 85 11,003 7,179
Total cost of shares $111,969 $241,653 $815,701 $985,492
Average cost per share – open market repurchases $563.04 $587.50 $588.14 $475.92
Average cost per share – employee surrenders $545.16 $647.08 $626.05 $454.46
Average cost per share – total $563.01 $587.52 $588.62 $475.76

View source version on businesswire.com: https://www.businesswire.com/news/home/20261030555612/en/

John Ravis, Investor Relations
[email protected]

Source: IDEXX Laboratories, Inc.

Released November 2, 2026

©2026 IDEXX Laboratories, Inc. All Rights Reserved.

Market Data copyright © 2026 QuoteMedia . Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia . Terms of Use .

Our website stores cookies on your device and discloses information in accordance with our Cookie Statement. Choose "Customize Settings" to control cookies. We may collect certain aggregate and anonymized data from your browser independent of your cookie preferences. Cookie Statement

Customize Settings Accept All

Company Logo

Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, or your device, and is mostly used to make the site work as you expect. The information does not usually identify you directly, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to learn more and change our default settings. Blocking some types of cookies may impact your experience of the site and the services we are able to offer.
More information

Allow All

Manage Consent Preferences

Strictly Necessary Cookies

Always Active

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Functional Cookies

Functional Cookies

These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.

Back Button

Cookie List

Search Icon

Filter Icon

Clear

  • checkbox label label

Apply Cancel

Consent Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Reject All Confirm My Choices

Powered by Onetrust

October 01, 2026 11:30am EDT

WESTBROOK, Maine--(BUSINESS WIRE)-- IDEXX Laboratories, Inc.

(Nasdaq: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2026 third quarter financial results for Monday, November 2, 2026, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day.

Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q3 2026 Earnings Snapshot through a link on the IDEXX website, www.idexx.com/investors

. An archived edition of the webcast will be available after 1:00 p.m. ET on that day via the same link and will remain available for one year.

The live call also will be accessible by telephone. To listen to the live conference call, please dial 1-800-330-6730 or 1-213-279-1575 and reference passcode 715328.

About IDEXX Laboratories, Inc.

IDEXX is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions—to advance medical care, improve efficiency, and build thriving practices. Our innovations also help measure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500™ Index. Headquartered in Maine, IDEXX employs approximately 11,000 people and offers solutions and products to customers in more than 175 countries and territories. For more information about IDEXX, visit: www.idexx.com

.

September 17, 2026 3:00am EDT

Expanded testing menu now detects more intestinal parasites during routine visits

WESTBROOK, Maine--(BUSINESS WIRE)-- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the expansion of its Faecal Dx™ antigen testing platform in the United Kingdom with taeniid tapeworm, including Taenia and Echinococcus species. Proven to detect up to twice as many intestinal parasite infections earlier than faecal flotation alone,1 Faecal Dx antigen testing delivers broader parasite detection in a single test for both wellness and sick-pet care.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260917879004/en/

IDEXX Faecal Dx™ antigen testing platform menu

Since launching in 2012, more than 50 million Faecal Dx antigen tests have been run worldwide,2 reflecting consistent use in practice over time. With each menu expansion, Faecal Dx has grown into a diagnostic platform with increasing clinical scope.

“This advancement reflects how we innovate at IDEXX, developing platforms that grow with our customers as care evolves,” said Mike Erickson, President and CEO of IDEXX. “By broadening the insight available through Faecal Dx, we’re making faecal testing easier to incorporate into everyday decision-making, helping veterinary teams reach more pets with greater confidence.”

Taenia and Echinococcus species are recognized by the European Scientific Counsel Companion Animal Parasites (ESCCAP) as clinically important parasites.3,4 Due to its zoonotic risk, ESCCAP identifies Echinococcus species as one of the three key parasite groups requiring preventive control in dogs and cats.3 With this addition, Faecal Dx antigen testing now detects seven of the most clinically relevant intestinal parasite groups, including hookworm, roundworm, whipworm, flea tapeworm, taeniid tapeworms, Cystoisospora and Giardia (in select panels).

Current Faecal Dx antigen testing panels and profiles for IDEXX Reference Laboratories customers in the United Kingdom now include taeniid tapeworm detection at no additional cost.* Faecal Dx test results returning positive for taeniid tapeworms will automatically initiate a complimentary follow-up Echinococcus RealPCR test.*

For more information, please visit the Faecal Dx antigen testing

web page.

Prompts

IDEXX Laboratories, Inc. (ticker IDXX), listed in United States.

ETFs Holding IDEXX Laboratories, Inc.

ETF Weight in ETF Shares Market value As of
PCLG 2.69% 3,991 $ 2.231M Jul 31, 2026
MEDI 2.50% 1,591 $ 1.111M Nov 12, 2026
ACTS 2.35% 429 $ 225.843K Jun 30, 2026
RISN 2.19% 2,821 $ 1.57M Aug 31, 2026
PCGG 1.93% 211 $ 111.079K Jun 30, 2026
JGRW 1.75% 2,764 $ 1.539M Aug 31, 2026
RONB 1.72% 16,049 $ 8.449M Jun 30, 2026
TOLL 1.56% 1,640 $ 912.972K Aug 31, 2026
MID 1.33% 2,505 $ 1.395M Aug 31, 2026
CAML 1.31% 8,628 $ 4.824M Jul 31, 2026
AVMV 1.28% 15,195 $ 10.646M Nov 16, 2026
TCAL 1.19% 5,620 $ 3.938M Nov 17, 2026
TMED 1.18% 515 $ 271.117K Jun 30, 2026
GQI 1.17% 5,719 $ 3.011M Jun 30, 2026
NVIR 1.14% 126 $ 66.331K Jun 30, 2026
CBLS short -1.07% -1,060 $ -592.614K Jul 31, 2026
FEMG 0.88% 112 $ 58.961K Jun 30, 2026
PGRO 0.79% 3,005 $ 1.673M Aug 31, 2026
SXQG 0.76% 647 $ 451.619K Nov 12, 2026
SROI 0.74% 247 $ 138.09K Jul 31, 2026
JMID 0.66% 278 $ 155.421K Jul 31, 2026
DUHP 0.63% 176,417 $ 123.143M Nov 12, 2026
WBIL 0.61% 351 $ 184.78K Jun 30, 2026
MFSG 0.49% 3,348 $ 1.864M Aug 31, 2026
AVMC 0.49% 3,885 $ 2.722M Nov 16, 2026
SPIN 0.46% 295 $ 206.692K Nov 16, 2026
ACLC 0.46% 2,667 $ 1.485M Aug 31, 2026
JSTC 0.38% 1,612 $ 1.129M Nov 17, 2026
ESLV 0.38% 96 $ 53.671K Jul 31, 2026
ESLG 0.35% 146 $ 81.624K Jul 31, 2026
TUG 0.31% 204 $ 107.394K Jun 30, 2026
ESUM 0.30% 965 $ 539.503K Jul 31, 2026
NANC 0.29% 1,106 $ 774.919K Nov 17, 2026
AVUQ 0.28% 1,709 $ 1.197M Nov 16, 2026
VFQY 0.24% 2,224 $ 1.238M Aug 31, 2026
SEIQ 0.24% 2,981 $ 1.569M Jun 30, 2026
FTLS 0.21% 7,635 $ 0.00 Nov 16, 2026
DFVX 0.21% 1,716 $ 1.198M Nov 12, 2026
BAMG 0.19% 448 $ 249.397K Aug 31, 2026
TCAF 0.19% 29,390 $ 20.592M Nov 17, 2026
CAPE 0.19% 865 $ 455.371K Jun 30, 2026
TUGN 0.19% 284 $ 149.509K Jun 30, 2026
AVSU 0.18% 1,262 $ 884.22K Nov 16, 2026
RGLO 0.17% 1,056 $ 555.921K Jun 30, 2026
RILA 0.15% 113 $ 63.175K Jul 31, 2026
FLSP 0.15% 2,618 $ 1.378M Jun 30, 2026
AVUS 0.14% 29,668 $ 20.787M Nov 16, 2026
AVLC 0.13% 3,006 $ 2.106M Nov 16, 2026
LGDX 0.13% 262 $ 183.57K Nov 17, 2026
DFSU 0.13% 4,354 $ 3.039M Nov 12, 2026
DXUV 0.12% 11,031 $ 7.7M Nov 12, 2026
XMAG 0.12% 382 $ 266.644K Nov 13, 2026
HBTA 0.11% 486 $ 270.551K Aug 31, 2026
MPLY 0.11% 30 $ 16.772K Jul 31, 2026
SEIM 0.09% 2,674 $ 1.408M Jun 30, 2026
DFAC 0.09% 113,701 $ 79.366M Nov 12, 2026
IALT 0.09% 10,706 $ 7.501M Nov 16, 2026
MODL 0.09% 1,715 $ 902.845K Jun 30, 2026
DFAU 0.09% 16,023 $ 11.184M Nov 12, 2026
VSLU 0.08% 859 $ 452.212K Jun 30, 2026
DFUS 0.08% 24,671 $ 17.221M Nov 12, 2026
DCOR 0.07% 47,732 $ 33.318M Nov 12, 2026
TACU 0.07% 19 $ 13.312K Nov 17, 2026
APUE 0.07% 3,041 $ 1.693M Aug 31, 2026
NTSD 0.06% 44 $ 23.163K Jun 30, 2026
VOXP 0.06% 6 $ 3,354.42 Jul 31, 2026
HCMT 0.05% 550 $ 307.489K Jul 31, 2026
GDE 0.05% 444 $ 247.17K Aug 31, 2026
NTSX 0.05% 1,307 $ 688.057K Jun 30, 2026
ACVF 0.04% 116 $ 64.852K Jul 31, 2026
MSLC 0.04% 3,081 $ 1.715M Aug 31, 2026
AVLV 0.04% 13,962 $ 9.782M Nov 16, 2026
RAA 0.03% 363 $ 191.098K Jun 30, 2026
CSHP 0.03% 158 $ 110.703K Nov 16, 2026
GSPY 0.03% 252 $ 176.564K Nov 17, 2026
AAUS 0.02% 181 $ 120K Nov 18, 2026
EBI 0.01% 135 $ 75.153K Aug 31, 2026
GEW 0.01% 36 $ 20.041K Aug 31, 2026
NPFE 0.00% 7 $ 3,913.49 Jul 31, 2026
ACGR 0.00% 186 $ 103.544K Aug 31, 2026
CORO 0.00% 50 $ 34.814K Nov 16, 2026
NTRL 0.00% 396 $ 0.00 Nov 16, 2026